Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$4.17
+11.7%
$22.29
$3.08
$597.60
$6.65M0.0354,000 shs144,888 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.28
-1.5%
$1.04
$0.81
$1.76
$30.27M0.79101,886 shs47,419 shs
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
$0.05
$0.05
$0.13
$0.38
$4.69M1.33338,444 shs39,643 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.43
-2.4%
$0.31
$0.24
$1.47
$30.36M0.13653,419 shs300,667 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
+11.01%+0.31%-27.88%-93.00%-98.97%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+10.17%+15.04%+38.30%+42.86%-4.41%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.00%+5.03%-20.80%-9.17%+62.30%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+1.72%+32.34%+32.07%+71.53%-47.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.7492 of 5 stars
0.03.00.00.02.81.70.0
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.1606 of 5 stars
3.75.00.00.00.00.80.6
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.2247 of 5 stars
3.63.00.04.60.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00681.25% Upside
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.00
N/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13631.85% Upside

Current Analyst Ratings Breakdown

Latest MATN, CYCC, OVID, and ENLV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
4/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$40K164.52N/AN/A($58.87) per share-0.07
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$570K53.27N/AN/A$0.96 per share0.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$56.00N/AN/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)

Latest MATN, CYCC, OVID, and ENLV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A

Latest MATN, CYCC, OVID, and ENLV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2025
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$36.004/29/20254/29/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.60
5.60
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
N/A
0.17
0.17
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93

Institutional Ownership

CompanyInstitutional Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
0.07%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%

Insider Ownership

CompanyInsider Ownership
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
96.90%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
39.22%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
13.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
141.58 million49,000Optionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Mateon Therapeutics, Inc. stock logo
MATN
Mateon Therapeutics
1390.24 millionN/ANot Optionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable

Recent News About These Companies

Ovid Therapeutics Inc. (OVID) - Yahoo Finance
Ovid Therapeutics Inc Chart - Morningstar
Juneberry Farm in Ovid opens for u-pick season
Ovid man, 81, charged with DWI after near-crash
Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$4.16 +0.44 (+11.66%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.28 -0.02 (-1.54%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Mateon Therapeutics stock logo

Mateon Therapeutics OTCMKTS:MATN

$0.05 0.00 (0.00%)
As of 07/9/2025

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.43 -0.01 (-2.38%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.